MedTrace Logo

The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting

NCT05772676 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2023-03-16

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of Aprepitant + standard antiemetic regimen in reducing postoperative nausea and vomiting after laparoscopic gastric sleeve versus placebo + standard antiemetic regimen

Conditions

  • Obesity
  • Nausea and Vomiting, Postoperative

Interventions

DRUG

Aprepitant

80 or 125 mg tablet + standard antiemetic regimen, once two hours before surgery

OTHER

Placebo

Placebo + standard antiemetic regimen, once two hours before surgery

Sponsors & Collaborators

  • Hospital General Tlahuac

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-01-01
Completion
2023-04-01

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05772676 on ClinicalTrials.gov